Physician profile
Ciji S Smith
NPI 1609582097
$3,293.08
in general payments reported to CMS, 2019-2025
27 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $255 · 2024: $1,483 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.11 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $851.64 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $446.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $134.47 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $113.48 | 2024-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $97.47 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.89 | 2024-2025 | Jardiance |
| Dexcom, INC. | $62.18 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $55.55 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.02 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $46.42 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $44.04 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.80 | 2025 | Caplyta |
| Pfizer INC. | $40.28 | 2024 | |
| Boston Scientific Corporation | $38.34 | 2023-2024 | Superion Indirect Decompression System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.51 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $33.50 | 2024 | |
| Idorsia Pharmaceuticals US INC | $29.04 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $27.66 | 2024 | Contrave |
| Corcept Therapeutics | $24.43 | 2024 | Korlym |
| Gilead Sciences, INC. | $24.17 | 2024 | Epclusa |
| Axonics, INC. | $23.35 | 2024 | Axonics |
| Saluda Medical Americas, INC. | $21.04 | 2024 | Evoke |
| Glaxosmithkline, LLC. | $20.24 | 2023 | Trelegy Ellipta |
| Acella Pharmaceuticals, LLC | $19.75 | 2024 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $18.74 | 2025 | Capvaxive, Gardasil 9 |
| Amneal Pharmaceuticals LLC | $15.05 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciji Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.